Asunto(s)
Discapacidades del Desarrollo/etiología , Glucogenólisis/fisiología , Hipoglucemia/complicaciones , Hipoglucemia/fisiopatología , Glucemia/análisis , Niño , Preescolar , Discapacidades del Desarrollo/fisiopatología , Endocrinología/métodos , Epinefrina/metabolismo , Femenino , Gluconeogénesis/fisiología , Hormona del Crecimiento/metabolismo , Humanos , Hidrocortisona/metabolismo , Lactante , Insulina/metabolismo , Secreción de Insulina , Masculino , Enfermería Pediátrica/métodos , Valores de Referencia , Sensibilidad y Especificidad , Sociedades de EnfermeríaRESUMEN
Patients with type Ia glycogen storage disease (GSD) have been surviving well into adulthood since continuous glucose therapy was introduced in the 1970s, and there have been many documented successful pregnancies in women with this condition. Historically, few individuals with type Ib GSD, however, survived into adulthood prior to the introduction of granulocyte colony stimulating factor (G-CSF) in the late 1980s. There are no previously published reports of pregnancies in GSD type Ib. In this case report we describe the course and management of five successful pregnancies in three patients with GSD type Ib. Patient 1 experienced an increase in glucose requirement in all three of her pregnancies, starting from the second trimester onwards. There were no major complications related to neutropenia except for oral ulcers. The infants did well, except for respiratory distress in two of them at birth. Patient 2 used cornstarch to maintain euglycemia, but precise dosing was not part of her regimen, and, hence, an increase in metabolic demands was difficult to demonstrate. She developed a renal calculus and urinary tract infection during her pregnancy and had chronic iron deficiency anemia but no neutropenia. The neonate did well after delivery. Patient 3 had poor follow-up during pregnancy. Increasing glucose requirements, worsening lipid profile, neutropenia associated with multiple infections, and anemia were noted. The newborn infant did well after delivery. In addition to the case reports, the challenges of the usage of G-CSF, the treatment of enterocolitis, and comparisons with the management of GSD Ia are discussed.
Asunto(s)
Glucosa/administración & dosificación , Enfermedad del Almacenamiento de Glucógeno Tipo I/terapia , Nacimiento Vivo , Atención Perinatal , Complicaciones del Embarazo/terapia , Almidón/administración & dosificación , Adulto , Biomarcadores/sangre , Glucemia/metabolismo , Vías de Administración de Medicamentos , Esquema de Medicación , Femenino , Enfermedad del Almacenamiento de Glucógeno Tipo I/sangre , Enfermedad del Almacenamiento de Glucógeno Tipo I/complicaciones , Enfermedad del Almacenamiento de Glucógeno Tipo I/diagnóstico , Enfermedad del Almacenamiento de Glucógeno Tipo I/genética , Humanos , Lípidos/sangre , Embarazo , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/genética , Sobrevivientes , Factores de Tiempo , Resultado del TratamientoRESUMEN
Context: The rarest genetic form of congenital hyperinsulinism (HI) has been associated with dominant inactivating mutations in uncoupling protein 2 (UCP2), a mitochondrial inner membrane carrier that modulates oxidation of glucose vs amino acids. Objective: To evaluate the frequency of UCP2 mutations in children with HI and phenotypic features of this form of HI. Design: We examined 211 children with diazoxide-responsive HI seen at The Children's Hospital of Philadelphia (CHOP) between 1997 and October 2016. Setting: CHOP Clinical and Translational Research Center. Results: Of 211 cases of diazoxide-responsive HI, we identified 5 unrelated children with UCP2 mutations (5 of 211; 2.4%). All 5 were diagnosed with HI before 6 months of age; diazoxide treatment was only partly effective in 3 of the 5. Among the 5 cases, 4 unique mutations (3 missense and 1 splicing) were identified. Three mutations were novel; 1 was previously reported. In vitro functional assays showed 30% to 75% decrease in UCP2 activity. Two of the children, when not taking diazoxide, developed hypoketotic-hypoglycemia after fasting 15 to 20 hours; a similar trend toward hypoglycemia after fasting 24 hours occurred in 4 adult carriers. In contrast, both children and 2 of the 4 carriers developed symptomatic hypoglycemia 4 hours following oral glucose. Unusual oscillating glucose and insulin responses to oral glucose were seen in both cases and carriers. Conclusions: These data indicate that dominant UCP2 mutations are a more important cause of HI than has been recognized and that affected individuals are markedly hypersensitive to glucose-induced hypoglycemia.
Asunto(s)
Glucemia/metabolismo , Hiperinsulinismo Congénito/genética , Ayuno/metabolismo , Insulina/metabolismo , Proteína Desacopladora 2/genética , Niño , Preescolar , Hiperinsulinismo Congénito/tratamiento farmacológico , Hiperinsulinismo Congénito/metabolismo , Análisis Mutacional de ADN , Diazóxido/uso terapéutico , Femenino , Prueba de Tolerancia a la Glucosa , Heterocigoto , Humanos , Lactante , Recién Nacido , Masculino , Mutación , Mutación Missense , FenotipoRESUMEN
Recessive mutations of sulfonylurea receptor 1 (SUR1) and potassium inward rectifier 6.2 (Kir6.2), the two adjacent genes on chromosome 11p that comprise the beta-cell plasma membrane ATP-sensitive K(+) (K(ATP)) channels, are responsible for the most common form of congenital hyperinsulinism in children. The present study was undertaken to identify the genetic defect in a family with dominantly inherited hyperinsulinism affecting five individuals in three generations. Clinical tests were carried out in three of the patients using acute insulin responses (AIRs) to intravenous stimuli to localize the site of defect in insulin regulation. The affected individuals showed abnormal positive calcium AIR, normal negative leucine AIR, subnormal positive glucose AIR, and impaired tolbutamide AIR. This AIR pattern suggested a K(ATP) channel defect because it resembled that seen in children with recessive hyperinsulinism due to two common SUR1 mutations, g3992-9a and delPhe1388. Genetic linkage to the K(ATP) locus was established using intragenic polymorphisms. Mutation analysis identified a novel trinucleotide deletion in SUR1 exon 34 that results in the loss of serine 1387. Studies of delSer1387 in COSm6 cells confirmed that the expressed mutant protein assembles with Kir6.2 and trafficks to the plasma membrane, but it had no (86)Rb efflux ion transport activity. These results indicate that hyperinsulinism in this family is caused by a SUR1 mutation that is expressed dominantly rather than recessively.
Asunto(s)
Transportadoras de Casetes de Unión a ATP , Hiperinsulinismo/genética , Mutación Puntual , Canales de Potasio de Rectificación Interna , Canales de Potasio/genética , Receptores de Droga/genética , Adulto , Salud de la Familia , Femenino , Expresión Génica , Genes Dominantes , Haplotipos , Humanos , Hiperinsulinismo/congénito , Lactante , Recién Nacido , Insulina/metabolismo , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Masculino , Linaje , Polimorfismo Genético , Receptores de SulfonilureasRESUMEN
Familial leucine-sensitive hypoglycemia of infancy was described in 1956 as a condition in which symptomatic hypoglycemia was provoked by protein meals or the amino acid, leucine. The purpose of this study was to determine the genetic basis for hypoglycemia in a family diagnosed with leucine-sensitive hypoglycemia in 1960. Recently diagnosed family members showed a dominantly transmitted pattern of diazoxide-responsive hyperinsulinism (HI). However, they did not fit the characteristics of HI caused by glutamate dehydrogenase gene mutations, previously felt to explain leucine-sensitive hypoglycemia. Islet function was examined using acute insulin response (AIR) tests to calcium, leucine, glucose, and tolbutamide as well as oral protein tolerance tests. Five of five affected family members showed an abnormal positive calcium AIR, and two of five showed a positive leucine AIR. Protein-induced hypoglycemia was demonstrated in five of six affected subjects. Mutation analysis of four known HI genes (sulfonylurea receptor 1, Kir6.2, glutamate dehydrogenase, and glucokinase) in family members identified an R1353H missense mutation in exon 33 of SUR1. (86)Rb(+) efflux and electrophysiological studies of R1353H SUR1 coexpressed with wild-type Kir6.2 in COSm6 cells demonstrated partially impaired ATP-dependent potassium channel function. Leucine-sensitive hypoglycemia in this family was found to result from a dominantly expressed SUR1 mutation.
Asunto(s)
Hipoglucemia/genética , Islotes Pancreáticos/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Mutación , Preescolar , Hiperinsulinismo Congénito/genética , Humanos , Leucina , MasculinoRESUMEN
Infants with congenital hyperinsulinism often require pancreatectomy. Recessive mutations of the ATP-dependent plasma membrane potassium channel (K(ATP)) genes, SUR1 and K(ir)6.2, cause diffuse hyperinsulinism. K(ATP) channel mutations can also cause focal disease through loss of heterozygosity for maternal 11p, resulting in expression of a paternal mutation. This study evaluated whether focal vs. diffuse hyperinsulinism could be diagnosed by acute insulin response (AIR) tests and whether arterial calcium stimulation/venous sampling (ASVS) could localize focal lesions. Fifty infants with diazoxide-unresponsive hyperinsulinism were studied. Focal lesions occurred in 70% of the cases. Positive AIR calcium occurred in 17 of 30 focal and 10 of 13 diffuse cases (P < 0.04). Positive AIR tolbutamide occurred in 27 of 30 focal vs. seven of 13 diffuse cases (P < 0.02); K(ATP) channel mutations were identified in four of the latter. ASVS localized the lesion in 24 of 33 focal cases (73%) but correctly diagnosed diffuse disease in only four of 13 cases. These results indicate that preoperative AIR tests do not distinguish focal vs. diffuse disease because some K(ATP) channel mutations retain responsiveness to tolbutamide. The ASVS test can be used to localize focal lesions in infants. The combination of ASVS, careful intraoperative histologic analysis, and surgical expertise succeeded in correcting hypoglycemia in 86% of the infants with focal hyperinsulinism.
Asunto(s)
Arterias , Calcio , Hiperinsulinismo Congénito/diagnóstico , Insulina/sangre , Páncreas/irrigación sanguínea , Transportadoras de Casetes de Unión a ATP , Calcio/administración & dosificación , Hiperinsulinismo Congénito/genética , Hiperinsulinismo Congénito/patología , Hiperinsulinismo Congénito/cirugía , Análisis Mutacional de ADN , Femenino , Glucosa/administración & dosificación , Humanos , Lactante , Recién Nacido , Masculino , Mutación , Páncreas/patología , Canales de Potasio/genética , Canales de Potasio de Rectificación Interna/genética , Cuidados Preoperatorios , Receptores de Droga , Receptores de Sulfonilureas , Tolbutamida/administración & dosificaciónRESUMEN
The purpose of this article is to describe diabetes diagnosed during the first 6 months of life. Neonatal diabetes, also known as congenital diabetes, presents a unique set of challenges for the pediatric healthcare provider. Neonatal diabetes is not type 1 diabetes. While the etiology of type 1 diabetes is multifactorial and includes genetic and environmental factors, neonatal diabetes is strictly a genetic condition. Management of children with neonatal diabetes, treatment of the disease, psychosocial considerations for the family, and nursing care required for this population are all included in this article. Unique issues related to the diagnosis of a genetic mutation resulting in a defect in the potassium channel are also discussed.
Asunto(s)
Diabetes Mellitus/congénito , Diabetes Mellitus/diagnóstico , Enfermedades del Recién Nacido/diagnóstico , Enfermedades del Recién Nacido/enfermería , Enfermería Neonatal/métodos , Diabetes Mellitus/enfermería , Fluidoterapia , Humanos , Recién Nacido , Insulina/uso terapéutico , Atención Posnatal/métodos , PronósticoRESUMEN
OBJECTIVES: To characterize the clinical features and insulin regulation in infants with hypoglycemia due to prolonged neonatal hyperinsulinism. STUDY DESIGN: Data were collected on 26 infants with hypoglycemia due to neonatal hyperinsulinism that later resolved. Acute insulin response (AIR) tests to calcium, leucine, glucose, and tolbutamide were performed in 11 neonates. Results were compared to children with genetic hyperinsulinism due to mutations of the adenosine triphosphate-dependent potassium (K(ATP)) channel and glutamate dehydrogenase (GDH). RESULTS: Among the 26 neonates, there were significantly more males, small-for-gestational-age infants, and cesarean deliveries. Only 5 of the 26 had no identifiable risk factor. Hyperinsulinism was diagnosed at a median age of 13 days (range, 2 to 180 days) and resolved by a median age of 181 days (range, 18 to 403 days). Diazoxide was effective in 19 of the 21 neonates treated. In the 11 neonates tested, the AIRs to calcium, leucine, glucose, and tolbutamide resembled those in normal controls and differed from genetic hyperinsulinism due to K(ATP) channel and GDH mutations. CONCLUSIONS: We define a syndrome of prolonged neonatal hyperinsulinism that is responsive to diazoxide, persists for several months, and resolves spontaneously. AIR tests suggest that both the K(ATP) channel and GDH have normal function.
Asunto(s)
Antihipertensivos/uso terapéutico , Diazóxido/uso terapéutico , Hiperinsulinismo/terapia , Hipoglucemia/terapia , Calcio/farmacología , Estudios de Casos y Controles , Nutrición Enteral , Ayuno , Femenino , Glucosa/farmacología , Humanos , Hiperinsulinismo/complicaciones , Hiperinsulinismo/diagnóstico , Hipoglucemia/etiología , Hipoglucemiantes/farmacología , Lactante , Recién Nacido , Infusiones Intravenosas , Insulina/sangre , Insulina/metabolismo , Secreción de Insulina , Leucina/farmacología , Masculino , Estudios Prospectivos , Factores de Riesgo , Edulcorantes/farmacología , Tolbutamida/farmacologíaRESUMEN
OBJECTIVE: To describe seizure phenotypes associated with the hyperinsulinism/hyperammonemia syndrome (HI/HA), which is caused by gain of function mutations in the enzyme glutamate dehydrogenase (GDH). STUDY DESIGN: A retrospective review of records of 14 patients with HI/HA. RESULTS: Nine patients had seizures as the first symptom of HI/HA, and six had seizures in the absence of hypoglycemia. No electroencephalogram (EEG) background abnormalities were identified. In four patients, EEG recordings during seizures in the setting of normal blood glucose contained generalized epileptiform discharges. EEGs of three of these patients showed 0.5- to 2-second generalized irregular spike-and-wave discharge at 3 to 6 Hz corresponding to eye blinks, eye rolling, or staring. The EEG of the fourth patient consisted of 20 seconds of generalized regular spike-and-wave discharge at 3 Hz in the clinical context of staring and unresponsiveness. In two patients, seizure control worsened with carbamezapine or oxcarbezapine treatment. CONCLUSIONS: In patients with HI/HA, generalized seizures are common and can occur in the absence of hypoglycemia. The drugs carbamazepine and oxcarbazepine should be used with caution for treatment. Pathogenesis of epilepsy in these patients may be related to effects of GDH mutations in the brain, perhaps in combination with effects of recurrent hypoglycemia and chronic hyperammonemia.
Asunto(s)
Epilepsia Generalizada/etiología , Glutamato Deshidrogenasa/genética , Hiperamonemia/genética , Hiperinsulinismo/genética , Mutación , Convulsiones/diagnóstico , Adolescente , Glucemia/metabolismo , Niño , Preescolar , Electroencefalografía , Epilepsia Generalizada/genética , Epilepsia Generalizada/fisiopatología , Femenino , Humanos , Hipoglucemia/genética , Lactante , Estudios RetrospectivosRESUMEN
Children with congenital hyperinsulinism are at risk for recurring, severe episodes of hypoglycemia that can cause seizures, brain damage, and developmental delay. To assess the frequency of permanent brain damage in this disorder, we carried out a telephone survey of 68 children who presented to The Children's Hospital of Philadelphia between 1980 and 2000. One third of the group had some degree of developmental delay. Those presenting in the first week of life and those with medically unresponsive hyperinsulinism were more likely to have delays. Early recognition and control of hypoglycemia are essential for preventing developmental delay in these children.